Ocera Therapeutics (OCRX -15.8%) prices its public offering of 4.2M shares of common stock at $6.00 per share. Underwriters over-allotment is 630K shares. Proceeds will be used to advance the clinical programs of OCR-002, working capital and general corporate purposes.
"We believe the combination of palatable clinical development risk, steady data/news flow, strong patent estate, and potential to meaningfully improve the treatment algorithm in an already greater than $1B HE market opportunity with a rapidly expanding patient demographic creates a highly favorable risk/reward at these levels," analyst Stephen Willey says.
: This time of the year the snow melts and you realize how much the dog eats. Had a dog but now a cat. He craps in a box for me. Eats mice.
joe kelly+ FollowFollowing- Unfollow|Send Message5 Apr 2013
: A box full of tzym no doubt. Not selling though. Minute I do it will turn to chocolate.
OCRX vs. ETF Alternatives
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.